Virpax Pharmaceuticals, Inc. (VRPX)
| Market Cap | 55.06M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| Shares Out | 11.72M |
| EPS (ttm) | -1.88 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,165,533 |
| Open | 4.89 |
| Previous Close | 4.96 |
| Day's Range | 4.67 - 4.97 |
| 52-Week Range | 3.70 - 36.00 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings Date | Nov 11, 2021 |
About VRPX
Virpax Pharmaceuticals, Inc., a preclinical stage biopharmaceutical company, develops and manufactures non-opioid and non-addictive pharmaceutical products using drug delivery systems for pain management. The company offers products, such as Epoladerm, a diclofenac metered-dose spray film for acute musculoskeletal pain; Probudur (LBL100), long-acting bupivacaine liposomal gel for postoperative pain management; OSF200 for chronic osteoarthritis of the knee; and NES100 (Envelta), an exogenous enkephalin intranasal spray for acute and chronic pain...
Financial Performance
Financial StatementsNews
Best Penny Stocks To Buy Today? Retail Traders Are Watching These Now
Penny stocks bouncing back after the stock market sell-off The post Best Penny Stocks To Buy Today? Retail Traders Are Watching These Now appeared first on Penny Stocks to Buy, Picks, News and Informati...
Virpax to Develop Intranasal Cannabidiol Product for the Management of Epilepsy in Adults and Children
BERWYN, Pa.--(BUSINESS WIRE)-- #pharma--Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ:VRPX), a company specializing in developing product candidates for pain management, CNS disorder...
Virpax® Pharmaceuticals Announces Closing of $40 Million Public Offering of Common Stock
BERWYN, Pa.--(BUSINESS WIRE)-- #pharma--Virpax® Pharmaceuticals Inc. (“Virpax” or the “Company”) (NASDAQ:VRPX), a company specializing in developing pharmaceutical products for pain management, today an...
Virpax® Pharmaceuticals Announces Pricing of $40 Million Public Offering of Common Stock
BERWYN, Pa.--(BUSINESS WIRE)-- #pharma--Virpax® Pharmaceuticals Inc. (“Virpax” or the “Company”) (NASDAQ:VRPX), a company specializing in developing pharmaceutical products for pain management, today an...
Virpax Pharmaceuticals Announces Poster Presentation for Envelta™ at PAINWeek 2021
BERWYN, Pa.--(BUSINESS WIRE)-- #PAINWeek--Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ:VRPX), today announced it will present a poster on Leucine Enkephalin as a potential analgesic...
Virpax Announces MMS019 Manufacturing and Supply Agreement
BERWYN, Pa.--(BUSINESS WIRE)-- #pharma--Virpax® Pharmaceuticals, Inc. ("Virpax" or the "Company") (NASDAQ:VRPX), a company specializing in developing product candidates for pain management, CNS and anti...
Short Squeeze Stocks: VRPX, CRDL and 3 Others Experts Think Are Ready to Pop
As we begin another week, here's a look at some of the best short squeeze stocks available to investors according to research from Fintel. The post Short Squeeze Stocks: VRPX, CRDL and 3 Others Experts ...
Should you invest in Virpax Pharma as stock soars more than 40%?
On Wednesday, Virpax Pharmaceuticals Inc. (NASDAQ:VRPX) shares soared more than 97% before pulling back later for a net intraday gain of 43%. The stock is now up more than 470% from its Monday close fol...
VRPX Stock: What Investors Are Saying About Virpax Pharma as Shares Continue to Fly
Shares of VRPX stock continue to blow up on Wednesday after Virpax Pharmaceuticals' massive business announcement on Tuesday. The post VRPX Stock: What Investors Are Saying About Virpax Pharma as Shares...
Why Virpax Pharmaceuticals Shares Are Soaring Today
Virpax Pharmaceuticals Inc (NASDAQ: VRPX) is surging higher Tuesday after the company announced that it received a written pre-investigational new drug response from the U.S. Food and Drug Administratio...
Here's why Virpax Pharmaceuticals is up 280% on Tuesday
Virpax Pharmaceuticals Inc. (NASDAQ: VRPX) said on Tuesday it received a written pre-IND (investigational new drug) response from the U.S. FDA (Food and Drug Administration) for MMS019 that supports fur...
VRPX Stock: 6 Things for Virpax Pharma Investors to Know as Shares Rocket Over 250%
Virpax Pharma (VRPX) stock is rocketing higher on Tuesday after getting a response from the FDA concerning an anti-viral barrier product. The post VRPX Stock: 6 Things for Virpax Pharma Investors to Kno...
Why Virpax Pharmaceuticals Stock Flying Higher?
Virpax Pharmaceuticals Inc (NASDAQ: VRPX) has received a written pre-investigational new drug (pre-IND) response from the FDA regarding MMS019. The drug candidate is a high-density molecular masking spr...
Virpax® Pharmaceuticals Receives FDA Response and Guidance on MMS019
BERWYN, Pa.--(BUSINESS WIRE)-- #pharma--Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ:VRPX), a company specializing in developing product candidates for pain management, CNS and anti...
Virpax Pharmaceuticals Reports 2021 Second Quarter Results and Recent Developments
BERWYN, Pa.--(BUSINESS WIRE)-- #earnings--Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ:VRPX), today announced its financial results for the quarter ended June 30, 2021, and other re...
Virpax® Pharmaceuticals Strengthens Board of Directors with the Appointment of Gerald W. Bruce and Michael F.
BERWYN, Pa.--(BUSINESS WIRE)-- #pharma--Virpax® Pharmaceuticals Inc. ("Virpax" or the "Company") (NASDAQ: VRPX), a company specializing in developing pharmaceutical product candidates for pain managemen...
Virpax Pharmaceuticals Provides Progress Update on Product Candidates
BERWYN, Pa.--(BUSINESS WIRE)-- #pharma--Virpax® Pharmaceuticals Inc. ("Virpax" or the "Company") (NASDAQ:VRPX), today is providing a progress update on its pipeline of product candidates following the C...
Virpax to Use Envelta™ IND Enabling Study Results for Two Additional Indications
BERWYN, Pa.--(BUSINESS WIRE)-- #pharma--Virpax® Pharmaceuticals, Inc. ("Virpax" or the "Company") (NASDAQ: VRPX), today announced that the Investigational New Drug (IND) Application enabling studies for...
Virpax Pharmaceuticals to Present at LD Micro Invitational XI Event on Wednesday, June 9th at 4:30 PM ET
BERWYN, Pa.--(BUSINESS WIRE)-- #pharma--Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ:VRPX), a company specializing in developing non-addictive, non-opioid pharmaceutical products fo...
Virpax Pharmaceuticals Reports 2021 First Quarter Results and Recent Developments
BERWYN, Pa.--(BUSINESS WIRE)-- #pharma--Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ:VRPX), today announced its financial results for the quarter ended March 31, 2021, and other rec...
Virpax Pharmaceuticals Engages Torreya Capital to Advise on Global Partnering Efforts
BERWYN, Pa.--(BUSINESS WIRE)-- #licensing--Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ:VRPX), today announced that the Company has engaged Torreya Capital, LLC (Torreya) to serve a...
Virpax's Anti-Viral Candidate Reduced Nasal, Brain Viral Load In Animal Study
Virpax Pharmaceuticals Inc (NASDAQ: VRPX) has announced preclinical results of MMS019, its anti-viral product candidate for respiratory viruses. MMS019 is a high-density molecular masking spray the Comp...
Virpax's MMS019 Reduced Nasal and Brain Viral Load in Animal Study
BERWYN, Pa.--(BUSINESS WIRE)-- #pharma--Virpax® Pharmaceuticals, Inc. ("Virpax" or the "Company") (NASDAQ:VRPX), a company specializing in developing pharmaceutical product candidates for pain managemen...
Virpax's Liposomal Bupivacaine Candidate Associated With No Neurotoxicity In Animal Studies
Virpax Pharmaceuticals Inc (NASDAQ: VRPX) has announced data from a sciatic nerve preclinical study designed to evaluate Probudur, Virpax's liposomal bupivacaine product candidate. This study's objectiv...
Virpax Announces Results of Probudur(TM) in Animal Study
BERWYN, PA / ACCESSWIRE / April 5, 2021 / Virpax® Pharmaceuticals, Inc. ("Virpax" or the "Company") (NASDAQ:VRPX), a company specializing in developing pharmaceutical product candidates for pain managem...